Literature DB >> 22460596

Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude.

Xiang-Yang Li1, Yong-Nian Liu, Xue-Jun Wang, Jun-Bo Zhu, Ming Yuan, Yong-Ping Li, Yong-Fang Li.   

Abstract

The aim of this study was to investigate the pharmacokinetics of sulfamethoxazole in native Han and Tibetan healthy Chinese subjects living chronically at high altitude. An open-labeled, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1,200 mg was administered orally to two groups: native Han and Tibetan volunteers living at high altitude (2,500-3,900 m [8,200-12,800 ft]). Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and metabolite N (4)-acetyl-sulfamethoxazole in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead electrocardiogram, and blood pressure monitoring. The protein binding was significantly higher in the native Tibetan group (70.5 %) compared to the native Han group (67.3 %) (p < 0.05). The binding of sulfamethoxazole to red blood cells was 7.4 and 8.3 % in the native Han and native Tibetan groups, respectively. There was no significant difference between the two groups. The AUC(0-∞) was significantly lower in the native Tibetan group compared to the native Han group (p < 0.05), and other pharmacokinetics parameters were found to have no significant difference between the two groups. This study found little changes in the disposition of sulfamethoxazole in these native healthy Tibetan Chinese subjects living at high altitude in comparison to native healthy Han Chinese subjects living at high altitude.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460596     DOI: 10.1007/s13318-012-0090-0

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  20 in total

1.  [The effect of rhodiola and acetazolamide on the sleep architecture and blood oxygen saturation in men living at high altitude].

Authors:  Zhende Ha; Yong'an Zhu; Xizhou Zhang; Jianhua Cui; Suping Zhang; Yong Ma; Wei Wang; Xinqiong Jian
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2002-09

2.  [High-altitude related illness].

Authors:  H Duplain; C Sartori; U Scherrer
Journal:  Rev Med Suisse       Date:  2007-08-02

Review 3.  Physiological adaptation to high altitude: oxygen transport in mammals and birds.

Authors:  C Monge; F León-Velarde
Journal:  Physiol Rev       Date:  1991-10       Impact factor: 37.312

4.  Urinary excretion of meperidine and normeperidine in man upon acute and chronic exposure to high altitude.

Authors:  W A Ritschel; C Paulos; A Arancibia; M Pezzani; M Agrawal; K Wetzelsberger; P W Lücker
Journal:  Methods Find Exp Clin Pharmacol       Date:  1996 Jan-Feb

Review 5.  The role of drugs in high altitude disorders.

Authors:  M Aslam; M Z Khan
Journal:  J Pak Med Assoc       Date:  1996-04       Impact factor: 0.781

6.  Hemoglobin concentration of pastoral nomads permanently resident at 4,850-5,450 meters in Tibet.

Authors:  C M Beall; M C Goldstein
Journal:  Am J Phys Anthropol       Date:  1987-08       Impact factor: 2.868

7.  Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse drug reactions.

Authors:  T P Reilly; P M Woster; C K Svensson
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

8.  Pharmacokinetics of lithium in healthy volunteers after exposure to high altitude.

Authors:  A Arancibia; C Paulos; J Chávez; W A Ritschel
Journal:  Int J Clin Pharmacol Ther       Date:  2003-05       Impact factor: 1.366

9.  Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude.

Authors:  W A Ritschel; C Paulos; A Arancibia; M A Agrawal; K M Wetzelsberger; P W Lücker
Journal:  J Clin Pharmacol       Date:  1998-06       Impact factor: 3.126

Review 10.  Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness.

Authors:  Andrew M Luks; Erik R Swenson
Journal:  Chest       Date:  2008-03       Impact factor: 9.410

View more
  2 in total

Review 1.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

2.  Regulation of CYP450 and drug transporter mediated by gut microbiota under high-altitude hypoxia.

Authors:  Xue Bai; Jianxin Yang; Guiqin Liu; Junbo Zhu; Qian Wang; Wenqi Gu; Linli La; Xiangyang Li
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.